HOME >> MEDICINE >> NEWS
Transplant patients keep their new kidney longer with a CellCept-based drug combination

24 July 2006, Basel, Switzerland -- The largest ever comparative transplantation study, involving 1,645 kidney transplant patients, has revealed the best immunosuppressant drug regimen that will give patients a better chance of a normal life. CellCept (mycophenolate mofetil) plus low-dose tacrolimus, corticosteroids and IL-2 induction therapy was shown to be the top combination to prevent patients rejecting their new kidney whilst maximising the function and life of the new organ.

The results at 12 months showed significantly improved kidney function (15%, p<0.0001), up to a further 65% reduction in early rejection and up to 6% improvement in organ survival for patients receiving the CellCept plus low-dose tacrolimus combination. This could mean that, if all first time kidney recipients were to take this regimen, nearly 2,500* organs could be saved in the first year post transplant.

"The results of the SYMPHONY study are an exciting and long-awaited development for both patients and doctors," commented lead investigator, Professor Henrik Ekberg, from University Hospital, Malm, Sweden, following the study's presentation at the World Transplant Congress, Boston. "New immunosuppressant drugs have successfully reduced the rejection rates of the new organ. However, patients still face developing serious side effects from the life long use of some of these drugs. The focus is now to define the optimal balance of these combinations in order to prolong further the life of the patient and their transplanted organ. SYMPHONY now provides the answer for doctors that the best regimen for patients today is CellCept and low dose tacrolimus, steroids and induction therapy."

To prevent rejection of a new kidney by the patient's immune system, immunosuppressant combinations have traditionally contained high dose calcineurin inhibitor's (CNIs), which are now known to cause kidney damage due to toxic side effects. This damage can lead to loss of the n
'"/>

Contact: Helen swift
Helen.Swift@Ketchum.com
44-207-611-3637
Ketchum
24-Jul-2006


Page: 1 2

Related medicine news :

1. Transplanting human gut bugs into mice helps understanding of metabolic system
2. Transplanting organs from animals to humans -- what are the barriers?
3. Childrens surgeon to present results of new anti-rejection protocol at World Transplant Congress
4. Transplantation Report 2005
5. Transplantation of sperm stem cells restores fertility after chemotherapy
6. Transplanting kidneys which have stones poses little risk to organs viability
7. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
8. Comparison of obstetric outcomes between on-call and patients own obstetricians
9. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
10. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
11. Happier hospitals means healthier patients

Post Your Comments:
(Date:3/31/2015)... (PRWEB) March 31, 2015 As the ... Fitness is pledging to have a mobile-friendly website online ... is part of Chunk Fitness’ continued commitment to bring ... growing user base. All of the same great fitness ... it will be substantially easier to read while browsing ...
(Date:3/31/2015)... CA (PRWEB) March 31, 2015 Cosmetic ... on the Internet, is proudly enduring adding news to ... doctors and the consumers of plastic surgery and cosmetic ... more user-friendly pages and interconnected sections, the Cosmetic Town ... newest addition to the Cosmetic Town site navigation, News ...
(Date:3/31/2015)... 31, 2015 In conjunction with ... April 1-7, the Mesothelioma Applied Research Foundation (Meso ... program, to complement its existing work in mesothelioma ... part of the Meso Foundation’s mission, we want ... diseases related to asbestos, including mesothelioma,” said the ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 In ... (ADS) is offering advice for buying from a ... Dealers Association (NMEDA) is a nonprofit organization that ... in the manufacturing and installation of mobility equipment. ... in the industry that consistently adhere to the ...
(Date:3/31/2015)... March 31, 2015 Calling all runners, walkers ... and other tick-borne diseases! The first annual “Lyme Walk & ... Park in Stamford, CT. The event, hosted by Lyme ... will raise funds to support research and education about Lyme ... to all ages and abilities, will feature 5K and 10K ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town is Now Transforming so Consumer can Better Navigate 2Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3Health News:Advanced Driving Systems Celebrates National Disability Month 2Health News:Lyme Research Alliance & Tick-Borne Disease Alliance to Kick-Off 1st “Lyme Walk & Run” Event, April 26 2
(Date:3/31/2015)...  Dr. Renu Razdan of leading Indian CRO ... Congress in April to discuss the latest, progressive announcement regarding ... drugs below: India,s Drugs ... Health that if a new drug is approved and marketed ... India with waiver of clinical trial ...
(Date:3/31/2015)... ALPHARETTA, Ga. , March 31, 2015   ... Health Care, today announced it was awarded a new ... line of face masks. Effective March 1, 2015, Halyard,s ... masks with SO SOFT* lining, will be available to ... as well as 15,000 ambulatory surgery centers, physician practices ...
(Date:3/31/2015)... NEW YORK , March 31, 2015 ... ) announced today that it intends to expand its ... fully human monoclonal antibody targeting eotaxin-1. Bullous Pemphigoid is ... approximately 60,000 patients in the US and ... expects to start enrolling patients in a Phase II ...
Breaking Medicine Technology:Max Neeman to Discuss India's Orphan Drug Regulations at WOD 2015 2Halyard Health Signs First GPO Contracts As Independent Company 2Halyard Health Signs First GPO Contracts As Independent Company 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 2Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 4
Cached News: